Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Alto Neuroscience for Securities Law Violations

Strategic Insights

— 1 min read

Alto Neuroscience, Inc. ("Alto") is facing a class action lawsuit for alleged violations of federal securities laws. The lawsuit claims that the Company made false and misleading statements regarding the effectiveness of ALTO-100 for treating major depressive disorder ("MDD"). Shareholders who purchased shares during the class period, which includes the initial public offering ("IPO") on February 2, 2024, and subsequent period ending October 22, 2024, may be eligible to participate in the lawsuit.

Key Takeaways:

  • Alto Neuroscience, Inc. is facing a class action lawsuit for alleged securities law violations.
  • The lawsuit claims that the Company made false and misleading statements regarding the effectiveness of ALTO-100 for treating MDD.
  • The class period includes the initial public offering ("IPO") on February 2, 2024, and subsequent period ending October 22, 2024.
  • Shareholders who purchased shares during this period may be eligible to participate in the lawsuit.
  • DJS Law Group is handling the case and encourages investors to register to participate.
  • The primary focus of DJS Law Group is to enhance investor return through balanced counseling and aggressive advocacy.
  • The clients of DJS Law Group include some of the largest and most sophisticated hedge funds and alternative asset managers in the world.

Statistics:

  • Initial public offering ("IPO") date: February 2, 2024
  • Class period: February 2, 2024 to October 22, 2024
  • Deadline to register to participate: September 19, 2025
  • Number of alleged securities law violations: 1

Sources:

  • PRNewswire, "Class Action Lawsuit Filed Against Alto Neuroscience for Securities Law Violations"
  • DJS Law Group LLP, "Press Release regarding class action lawsuit"

Read more